MA45801B1 - Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine - Google Patents
Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptineInfo
- Publication number
- MA45801B1 MA45801B1 MA45801A MA45801A MA45801B1 MA 45801 B1 MA45801 B1 MA 45801B1 MA 45801 A MA45801 A MA 45801A MA 45801 A MA45801 A MA 45801A MA 45801 B1 MA45801 B1 MA 45801B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- antigen
- lepr
- binding fragments
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne des anticorps et des fragments de liaison à l'antigène d'anticorps qui se lient au récepteur de la leptine (lepr), et des procédés de leur utilisation. Selon certains modes de réalisation, l'invention concerne des anticorps et des fragments de liaison à l'antigène d'anticorps qui se lient au lepr et antagonisent la signalisation par lepr. Dans certains modes de réalisation, l'invention concerne des anticorps et des fragments de liaison à l'antigène d'anticorps qui se lient au lepr en présence ou en l'absence de leptine. Dans d'autres modes de réalisation, l'invention comprend des anticorps et des fragments de liaison à l'antigène d'anticorps qui présentent un agonisme partiel de la signalisation lepr. Les anticorps et les fragments de liaison à l'antigène de la présente invention sont utiles pour le traitement de divers états, comprenant, entre autres, la cachexie liée à l'insuffisance cardiaque congestive, la cachexie pulmonaire et la cachexie cancéreuse, les troubles auto-immuns tels que la maladie intestinale inflammatoire, le lupus érythémateux, la sclérose en plaques, le psoriasis, les maladies cardiovasculaires, l'hypertension artérielle, les troubles neurodégénératifs, la dépression, le cancer tel que le carcinome hépatocellulaire, le mélanome, le cancer du sein, et d'autres maladies et troubles associés à ou provoqués par une signalisation de leptine élevée.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419062P | 2016-11-08 | 2016-11-08 | |
| PCT/US2017/060690 WO2018089532A1 (fr) | 2016-11-08 | 2017-11-08 | Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45801A1 MA45801A1 (fr) | 2020-07-29 |
| MA45801B1 true MA45801B1 (fr) | 2021-11-30 |
Family
ID=60409473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45801A MA45801B1 (fr) | 2016-11-08 | 2017-11-08 | Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10550192B2 (fr) |
| EP (2) | EP3538554B1 (fr) |
| JP (4) | JP7042816B2 (fr) |
| KR (1) | KR102563568B1 (fr) |
| CN (1) | CN110167965A (fr) |
| AU (2) | AU2017359439B2 (fr) |
| CA (1) | CA3043365A1 (fr) |
| CL (3) | CL2019001263A1 (fr) |
| CO (1) | CO2019004672A2 (fr) |
| DK (1) | DK3538554T3 (fr) |
| EA (1) | EA201991075A1 (fr) |
| ES (1) | ES3040144T3 (fr) |
| FI (1) | FI3538554T3 (fr) |
| HR (1) | HRP20251165T1 (fr) |
| IL (2) | IL266426B (fr) |
| LT (1) | LT3538554T (fr) |
| MA (1) | MA45801B1 (fr) |
| MX (2) | MX2019005397A (fr) |
| MY (2) | MY191256A (fr) |
| PH (1) | PH12019500988A1 (fr) |
| PL (1) | PL3538554T3 (fr) |
| PT (1) | PT3538554T (fr) |
| RS (1) | RS67214B1 (fr) |
| SG (1) | SG10201913470SA (fr) |
| SI (1) | SI3538554T1 (fr) |
| SM (1) | SMT202500327T1 (fr) |
| UA (1) | UA127678C2 (fr) |
| WO (1) | WO2018089532A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI824372B (zh) | 2015-10-12 | 2023-12-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| FI3538554T3 (fi) | 2016-11-08 | 2025-09-24 | Regeneron Pharma | Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria |
| BR112020012011A2 (pt) | 2017-12-18 | 2020-11-24 | Regeneron Pharmaceuticals, Inc. | moléculas de ligação a antígeno biespecífica isolada e de ligação a antígeno biespecífica ou cadeia de imunoglobulina, composição farmacêutica, recipiente ou dispositivo de injeção, ácido nucleico isolado, vetor isolado, célula hospedeira isolada, métodos para tratar uma doença ou condição, para tratar uma condição de lipodistrofia em um sujeito, para produzir uma molécula de ligação a antígeno biespecífica, e, para administrar uma molécula de ligação a antígeno biespecífica isolada ou composição farmacêutica. |
| US11608381B2 (en) | 2018-04-06 | 2023-03-21 | Regeneron Pharmaceuticals, Inc. | Methods of treatment using a leptin receptor agonist antibody |
| WO2020016160A1 (fr) * | 2018-07-16 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthode de traitement de maladies neurologiques |
| WO2020131910A1 (fr) | 2018-12-18 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Compositions et procédés permettant d'améliorer le poids corporel et la masse musculaire maigre à l'aide d'antagonistes dirigés contre le récepteur de la leptine, gdf8 et activine a |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| US20230263673A1 (en) * | 2020-07-17 | 2023-08-24 | Sumitomo Seika Chemicals Co., Ltd. | Absorber |
| JP2023543409A (ja) * | 2020-09-15 | 2023-10-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 疼痛に対するｌｅｐｒアゴニストの使用 |
| CN118436632B (zh) * | 2024-07-05 | 2024-08-30 | 四川大学华西第二医院 | Teriflunomide在制备预防和/或治疗原发性纤毛不动综合征的药物中的用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643748A (en) | 1994-09-14 | 1997-07-01 | Progenitor, Inc. | HU-B1.219, a novel human hematopoietin receptor |
| US6451523B1 (en) | 1994-09-14 | 2002-09-17 | Interneuron Pharmaceuticals, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| US5912123A (en) | 1994-09-14 | 1999-06-15 | Progenitor, Inc. | Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology |
| US5856098A (en) | 1994-09-14 | 1999-01-05 | Progenitor, Inc. | Detection of a leptin receptor variant |
| US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
| US6977240B1 (en) | 1995-11-27 | 2005-12-20 | Millenium Pharmaceuticals, Inc. | Methods of using the OB receptor antibodies to treat bodyweight disorders |
| US20050019325A1 (en) * | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| DE69739677D1 (de) | 1996-01-08 | 2010-01-07 | Genentech Inc | OB Rezeptor-Variante und Liganden |
| US7063958B1 (en) * | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
| AU2476301A (en) | 1996-01-16 | 2001-05-24 | Rockefeller University, The | DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof |
| AU1833197A (en) | 1996-01-18 | 1997-08-11 | Progenitor, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| DE69735477T2 (de) | 1996-01-23 | 2006-11-30 | Indevus Pharmaceuticals, Inc., Lexington | Process zur verwendung des obese-gens und seines genprodukts zur stimulierung der entwicklung von haemotopoietischen zellen |
| US7067472B1 (en) | 1996-06-04 | 2006-06-27 | The Scripps Research Institute | Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies |
| US5965521A (en) | 1997-02-25 | 1999-10-12 | Eli Lilly Company | Pulsatile delivery of leptin receptor ligands |
| IL120733A0 (en) | 1997-04-29 | 1997-08-14 | Yeda Res & Dev | Leptin as an inhibitor of cell proliferation |
| US6696411B1 (en) | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
| AU767068B2 (en) | 1999-06-11 | 2003-10-30 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of leptin activity |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| FR2852397B1 (fr) | 2003-03-10 | 2005-04-29 | Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal. | |
| ATE364630T1 (de) * | 2003-08-21 | 2007-07-15 | Vlaams Interuniv Inst Biotech | Neuer leptin-antagonist |
| DE10353593A1 (de) * | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| US8969291B2 (en) | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
| US7863240B2 (en) | 2004-10-08 | 2011-01-04 | Enzo Therapeutics, Inc. | Methods and uses of leptin in hepatocellular carcinoma |
| WO2006053883A1 (fr) | 2004-11-18 | 2006-05-26 | Vib Vzw | Domaine de fibronectine iii servant d'antagonistes de recepteurs de la leptine |
| US7307142B2 (en) * | 2004-11-26 | 2007-12-11 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Leptin antagonists |
| JP5255435B2 (ja) | 2005-04-26 | 2013-08-07 | メディミューン，エルエルシー | ヒンジドメイン操作による抗体エフェクター機能の調節 |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| GB0715216D0 (en) | 2007-08-03 | 2007-09-12 | Asterion Ltd | Leptin |
| EP2356270B1 (fr) | 2008-11-07 | 2016-08-24 | Fabrus Llc | Bibliothèques combinatoires d'anticorps et leurs utilisations |
| KR101962483B1 (ko) | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| MX2013009151A (es) | 2011-02-10 | 2013-08-29 | Roche Glycart Ag | Inmunoterapia mejorada. |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| MY170126A (en) | 2012-09-12 | 2019-07-05 | Genzyme Corp | Fc containing polypeptides with altered glycosylation and reduced effector function |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| KR101764800B1 (ko) * | 2013-02-20 | 2017-08-04 | 리제너론 파마슈티칼스 인코포레이티드 | 변형된 면역글로불린 중쇄 서열을 갖는 비인간 동물 |
| EP3108255B1 (fr) | 2014-02-18 | 2020-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques pour le traitement de maladies induites par la voie de signalisation du complexe nrp-1/obr |
| TWI824372B (zh) | 2015-10-12 | 2023-12-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| FI3538554T3 (fi) | 2016-11-08 | 2025-09-24 | Regeneron Pharma | Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria |
-
2017
- 2017-11-08 FI FIEP17801273.8T patent/FI3538554T3/fi active
- 2017-11-08 SI SI201731619T patent/SI3538554T1/sl unknown
- 2017-11-08 CN CN201780082335.4A patent/CN110167965A/zh active Pending
- 2017-11-08 LT LTEPPCT/US2017/060690T patent/LT3538554T/lt unknown
- 2017-11-08 DK DK17801273.8T patent/DK3538554T3/da active
- 2017-11-08 PL PL17801273.8T patent/PL3538554T3/pl unknown
- 2017-11-08 SM SM20250327T patent/SMT202500327T1/it unknown
- 2017-11-08 MX MX2019005397A patent/MX2019005397A/es unknown
- 2017-11-08 WO PCT/US2017/060690 patent/WO2018089532A1/fr not_active Ceased
- 2017-11-08 MA MA45801A patent/MA45801B1/fr unknown
- 2017-11-08 KR KR1020197016377A patent/KR102563568B1/ko active Active
- 2017-11-08 MY MYPI2019002549A patent/MY191256A/en unknown
- 2017-11-08 HR HRP20251165TT patent/HRP20251165T1/hr unknown
- 2017-11-08 SG SG10201913470SA patent/SG10201913470SA/en unknown
- 2017-11-08 AU AU2017359439A patent/AU2017359439B2/en active Active
- 2017-11-08 EP EP17801273.8A patent/EP3538554B1/fr active Active
- 2017-11-08 RS RS20250925A patent/RS67214B1/sr unknown
- 2017-11-08 EP EP25187542.3A patent/EP4613772A3/fr active Pending
- 2017-11-08 CA CA3043365A patent/CA3043365A1/fr active Pending
- 2017-11-08 JP JP2019523865A patent/JP7042816B2/ja active Active
- 2017-11-08 US US15/807,426 patent/US10550192B2/en active Active
- 2017-11-08 EA EA201991075A patent/EA201991075A1/ru unknown
- 2017-11-08 MY MYPI2022002957A patent/MY203682A/en unknown
- 2017-11-08 UA UAA201906354A patent/UA127678C2/uk unknown
- 2017-11-08 ES ES17801273T patent/ES3040144T3/es active Active
- 2017-11-08 PT PT178012738T patent/PT3538554T/pt unknown
-
2019
- 2019-05-02 IL IL266426A patent/IL266426B/en active IP Right Grant
- 2019-05-03 PH PH12019500988A patent/PH12019500988A1/en unknown
- 2019-05-07 CO CONC2019/0004672A patent/CO2019004672A2/es unknown
- 2019-05-08 CL CL2019001263A patent/CL2019001263A1/es unknown
- 2019-05-08 MX MX2023011233A patent/MX2023011233A/es unknown
-
2020
- 2020-01-07 US US16/736,760 patent/US11535675B2/en active Active
- 2020-01-30 IL IL272358A patent/IL272358B/en unknown
- 2020-03-05 CL CL2020000549A patent/CL2020000549A1/es unknown
- 2020-04-16 CL CL2020001023A patent/CL2020001023A1/es unknown
-
2021
- 2021-12-21 JP JP2021206917A patent/JP2022031969A/ja active Pending
-
2022
- 2022-11-17 US US18/056,411 patent/US20230235068A1/en active Pending
-
2023
- 2023-05-02 JP JP2023076083A patent/JP7611292B2/ja active Active
-
2024
- 2024-05-31 JP JP2024088870A patent/JP2024109952A/ja active Pending
-
2025
- 2025-02-28 AU AU2025201454A patent/AU2025201454A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45801B1 (fr) | Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine | |
| Sander et al. | Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract | |
| PH12022551750A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| MA40224B1 (fr) | Anticorps se liant aux protofibrilles ass améliorés | |
| WO2019014328A3 (fr) | Anticorps agonistes qui lient cd137 humain et leurs utilisations | |
| EA202092094A1 (ru) | Фенилпирролидиноновые агонисты формилпептидного рецептора 2 | |
| NO20083715L (no) | Antistoffer mot human IL-22 og anvendelser derav | |
| EA200870465A1 (ru) | Антагонисты рецептора il-8 | |
| MA35345B1 (fr) | Proteines de liaisons a un antigene ayant une liaison accrue a fcrn | |
| DK1966244T3 (da) | Anti-il-6-antistoffer der forebygger bindingen af il-6 sammensat af il-6ralfa til gp130 | |
| TW200612908A (en) | Antibodies against human interleukin-13 and uses therefor | |
| FR3078627B1 (fr) | Procedure de collecte de selles et procede de preparation d'un echantillon pour transplantation de microbiote fecal | |
| MA37946B1 (fr) | Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde | |
| FR3038517B1 (fr) | Utilisation de fragments fc modifies en immunotherapie | |
| MX2021015651A (es) | Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap). | |
| MA29723B1 (fr) | Composes | |
| MA33758B1 (fr) | Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes | |
| FR3063645B1 (fr) | Acefapc pour le traitement des maladies acetylcholine dependantes | |
| EA202092593A1 (ru) | Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение | |
| EP4406592A3 (fr) | Molécules de liaison thérapeutiques | |
| DE602004031003D1 (de) | Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden | |
| ATE423100T1 (de) | Neue chinolinverbindungen, die dazu in der lage sind, sich an den cb2-rezeptor zu binden | |
| MA39555B1 (fr) | Mutagenèse dirigée d'anticorps trem-1 pour réduire la viscosité | |
| FR2856595B1 (fr) | Methodes et compositions pour le traitement de deficits cognitifs. | |
| WO2005106489A3 (fr) | Diagnostics et therapies s'appliquant a des maladies associees aux recepteurs 5 des chimiokines c-c (ccr5) |